Dr. Thomas Lönngren, Strategic Advisor NDA Group and former head of the EMA, has been invited to speak at the The World’s First and most Prestigious Early and Managed Access Programmes, EMAP, event on the 24th – 26th October in London.
The Pharmaceutical Industry continues to turn to Early and Managed Access Programmes as the front line in fighting rare diseases and epidemic outbreaks. In many cases, critical patient or environmental conditions mean that any delay in access can be fatal.
Dr. Lönngren will present in the session ‘Regulatory development and alignment between the USA and Europe’ where he will discuss:
- Differences of market access in EU and US
- How to create a collaborative environment between the EMA and FDA – where to
- Analyse what Brexit means for the UK, EU and for medical technology
and pharmaceutical companies
To learn more about the event click here.
Dr. Thomas Lönngren, Strategic Advisor NDA Group